2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2075

CCR6⁺Foxp3⁺ Regulatory T Cells Regulate the Development of Collagen Induced Arthritis in T Cell Specific RORγt Transgenic Mice
Abstract Number: 1070

CD11c+ Dendritic Cells Play an Important Proinflammatory Role in Inflammatory Arthritis
Abstract Number: 2308

CD11c⁺ Cells Are Necessary for Myofibroblast Maintenance in Bleomycin-Induced Cutaneous Fibrosis
Abstract Number: 1064

CD1c-Expressing Myeloid Dendritic Cells From Joints of Rheumatoid Arthritis Patients Produce Increased Levels of T Cell-Attracting Chemokines and Strongly Activate Autologous T Cells
Abstract Number: 1494

CD40 Signaling Results in Microvascular Endothelial Dysfunction: A Possible Clue to the Pathogenesis of Scleroderma Vasculopathy
Abstract Number: 2503

CD8+Foxp3-CD103+ Regulatory T Cells Generated Ex Vivo with TGF-β Suppress Autoimmunity Through IL-10-Dependet Mechanism
Abstract Number: 603

Cell Bound Complement Activation Products Are Associated with Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 375

Cell Phone Based Automated Monitoring of Patients with Early Rheumatoid Arthritis
Abstract Number: 686

Cell-Type Specific Type I Interferon Signatures in Autologous Stem Cell Transplanted Lupus Patients: Different Molecular Behavior Between CD4+ T Cells and Monocytes
Abstract Number: 979

Cell-Type Specific Type I Interferon Signatures in Systemic Lupus Erythematosus and Viral Infection: What Makes the Difference?
Abstract Number: 234

Central Sensitization Is Associated with Spontaneous Pain in Knee Osteoarthritis
Abstract Number: 961

Cerebral Grey and White Matter Changes in Fibromyalgia Depend On Patients’ Age
Abstract Number: 2684

Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 Antibodies As Surrogate Markers for CNS Disease Severity in SLE
Abstract Number: 1319

Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial
Abstract Number: 834

Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].